Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.43 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.35 |
| ▸ | NPY2R | P49146 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737387 | 1.00 | PTPN1 (0.43) | PTPN1PTPN2HTR5ARAF1MAP2K1 | |
| SCHEMBL3732064 | 0.90 | HTR5A (0.41) | PTPN1PTPN2HTR5ARAF1MAP2K1 | |
| SCHEMBL3732067 | 0.88 | HTR5A (0.38) | PTPN1PTPN2HTR5ARAF1MAP2K1 | |
| SCHEMBL28771260 | 0.82 | HTR5A (0.42) | HTR5ARAF1MAP2K1SIGMAR1GPR88 | |
| SCHEMBL3742564 | 0.81 | PTPN1 (0.48) | PTPN1PTPN2PTPRC | |
| SCHEMBL3743087 | 0.80 | PTPN1 (0.48) | PTPN1PTPN2PTPRC | |
| SCHEMBL3735591 | 0.80 | PTPN1 (0.48) | PTPN1PTPN2PTPRC | |
| SCHEMBL3745755 | 0.79 | PTPN1 (0.46) | PTPN1PTPN2PTPRCSIGMAR1 | |
| SCHEMBL13041696 | 0.79 | PTPN1 (0.46) | PTPN1PTPN2PTPRCSIGMAR1 | |
| SCHEMBL3743444 | 0.71 | SIGMAR1 (0.45) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829737-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504389-B2 | Protein tyrosine phosphatase inhibitors and methods of use thereof | CEPTYR, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CEPTYR, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161592-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN2 5/4885HTR5A 2959/4885 |
| US-20090131374-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PPM1B, PTPN1, PTPN5 | PTPN1 2/4885PTPN2 5/4885HTR5A 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.